BIOMOTCPharmaceutical PreparationsFiscal year ends December 31

BIOMOLECULAR LIFE HOLDINGS, INC.

Financials through Q3 FY2015, quarter ended Sep 30, 2015Last filing: 10-Q on Nov 19, 2015

$0.79−0.02 (-2.47%)

Close on Oct 19, 2026

Market cap: $67.51M
P/E (TTM): –
Dividend yield: –

BIOMOLECULAR LIFE HOLDINGS, INC. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Cash & Equivalents	0.03	0.71	0.01
Cash & Short-Term Investments	0.03	0.71	0.01
Prepaid Expenses & Other	0.21	0.08	–
Total Current Assets	0.25	0.79	–
Property, Plant & Equipment	0	0	–
Intangible Assets	1.08	1.08	–
Total Assets	1.32	1.87	–
Accounts Payable	0.71	0.41	–
Accrued Expenses	0.22	0.43	–
Total Current Liabilities	5.83	6.33	–
Total Liabilities	5.83	6.33	–
Preferred Stock	0.00	0.00	–
Common Stock	0.00	0.00	–
Additional Paid-In Capital	101	95	–
Retained Earnings	-106	-100	–
Shareholders' Equity	-4.51	-4.47	-4.20
Noncontrolling Interest	0.66	0.70	–
Total Equity	-4.51	-4.47	-4.20
Total Liabilities & Equity	1.32	1.87	–
Shares Outstanding(shares)	46	17	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2015

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2014: 137.9%

Financial strength

Current ratio: 0.01
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –